One trial recorded a 93% reduction in viral signal in saliva treated with a plant protein. Before thinking about a cure, it is worth looking at what exactly was measured and where.
The idea sounds almost too clean: chew a piece of gum and drag with it the human papillomavirus that may inhabit your mouth. The headline circulates strongly, but the finding that supports it is more modest and, for that reason, more interesting. One team tested a formulation with a lablab bean protein on oral samples in the laboratory and observed that the viral particles were trapped. It didn’t cure anyone, because no one chewed that gum as a treatment. What happened is a preliminary step, the type of result that justifies further investigation without yet promising anything.
The molecular trap
The protagonist is FRIL, a protein from the lablab bean (Lablab purpureus), a legume cultivated for centuries. FRIL belongs to a group of proteins capable of recognizing and binding to certain sugars that decorate the surface of many viruses and bacteria. That gripping ability is the key to the entire experiment.
It is convenient to imagine HPV not as a diffuse cloud, but as a swarm of tiny, independent particles floating in saliva. The FRIL protein acts as a multi-armed hook that connects particles to others. and forces them to huddle together in clumps. These aggregates, being much larger, become easy to separate from the rest of the sample.
It is not destruction, it is agglutination. Understanding this difference is almost the entire article, because that is where the most common confusion arises: Clumping particles in a test tube is not the same as eliminating an infection in living tissue. Honest scientific dissemination begins precisely with that nuance.
What was measured, and what was not
The work was published on February 9, 2026. The team did not start from healthy volunteers chewing gum, but from something much more concrete: oral samples from patients with head and neck cancer, a type of tumor in which oral HPV has a known role.
They applied the formula with FRIL to these samples and then measured how much viral signal was detectable. The trial recorded a 93% drop in HPV signal in saliva and an 80% drop in mouthwash samples after treatment in the laboratory. They are striking numbers, but they must be read with surgical precision.
Those percentages do not describe how much virus disappeared from a patient’s body. They describe how much viral signal was no longer detected in a sample already extracted and treated on the work table. The difference is not a minor technicality: it is one thing for a method to make it more difficult to find the virus in a tube, and quite another for it to resolve an infection inside a person.
Mouth is not the same as everything else
Here appears another distinction that is often lost in the headlines. Oral HPV and genital HPV are the same type of virus acting in different locations, with different routes of infection and clinical problems.. An approach intended for the oral cavity, such as chewing gum, could only make sense, at best, in the presence of the virus in the mouth.

This matters because much of the fear associated with papilloma is concentrated in the genital area and its link with cervical cancer, where the effective and available tool already exists and is called a vaccine. A gum with FRIL would not compete with that vaccine or cover that territory. At most, it would explore a very specific niche: reducing the virus load one may have in one’s mouth.
And what purpose would it be to reduce that oral load? The reasonable hypothesis is twofold. On the one hand, it could decrease the amount of virus available in saliva, which theoretically would have implications for transmission. On the other hand, in patients with HPV-associated tumors, keeping the virus at bay in the area could be of clinical interest. The word that governs both ideas is the same: could.
The leap that has not yet been taken
Between what this study showed and what the headline suggests there is a methodological chasm. In the laboratory, the researcher controls the protein concentration, contact time, and sample conditions. In a real mouth none of that is guaranteed.
Chewing gum introduces variables that the test tube ignores. Saliva dilutes, enzymes degrade, and the contact time between the protein and the virus is short and irregular. It has not been proven that FRIL can withstand that environment or that it reaches the areas where the virus resides. Just because something works in isolation does not ensure that it works while you talk, swallow and breathe.
That is why the work itself does not claim that chewing gum cures an infection, prevents infections or prevents cancer. They are three different promises, and none of them have been tested. To affirm them, clinical trials would be needed: real people, comparison groups, follow-up over time and outcome measures that go beyond the signal in a sample.
Why the data is inflated when traveling
The journey of this discovery illustrates well how a prudent result is transformed into a promise when circulating through social networks. 93% is a memorable figure, and memory tends to stick with the number and release the context that accompanies it.. Thus, “93% reduction in viral signal in laboratory-treated samples” shrinks until it becomes “the chewing gum that eliminates papilloma.”

It is also advisable not to mix fronts. Proteins like FRIL have been studied for their ability to bind to other microorganisms as well, and it is easy to drag conclusions from one field to another. A result on bacteria is not a result on HPV, even if the protein involved is the same. Keeping each statement tied to your experiment is part of the craft in scientific health communication, where a misplaced comma can become false hope.
The promising and the prudent
None of this makes work irrelevant. Using a cheap and well-known plant protein to capture viral particles is an elegant strategy, and the format of a chewing gum as a vehicle makes sense: cheap, comfortable and designed precisely for the mouth. The idea of taking advantage of naturally occurring molecules to trap pathogens fits into an active and serious line of research.
The problem is not the science, but the distance between experiment and expectation. What exists today is a convincing proof of concept in oral samples treated in the laboratory. What does not exist is a validated product, nor evidence that chewing that gum does anything measurable within a person.
The next test is the one that will really decide the future of this idea: checking if FRIL retains its gripping power in the mouth, with saliva moving and the virus hidden in the tissue. Until such a trial exists and is published, the percentage will continue to describe what happens in a tube, not what happens in a throat. Will the molecular trap survive outside the laboratory, or will it dissolve with the first mouthful of saliva?